Market capitalization | GBP54.78b |
Enterprise Value | GBP67.07b |
P/E (TTM) P/E ratio | 21.77 |
EV/FCF (TTM) EV/FCF | 11.99 |
EV/Sales (TTM) EV/Sales | 2.14 |
P/S ratio (TTM) P/S ratio | 1.75 |
P/B ratio (TTM) P/B ratio | 3.91 |
Dividend yield | 4.15% |
Last dividend (FY23) | GBP0.56 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
23 Analysts have issued a GlaxoSmithKline forecast:
23 Analysts have issued a GlaxoSmithKline forecast:
Sep '24 |
+/-
%
|
||
Revenue | 31,311 31,311 |
6%
6%
|
|
Gross Profit | 22,113 22,113 |
3%
3%
|
|
EBITDA | 9,062 9,062 |
9%
9%
|
EBIT (Operating Income) EBIT | 5,745 5,745 |
13%
13%
|
Net Profit | 2,511 2,511 |
59%
59%
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Head office | United Kingdom |
CEO | Emma Walmsley |
Employees | 70,212 |
Founded | 1999 |
Website | www.gsk.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.